We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Allergy Therapeutics Plc | LSE:AGY | London | Ordinary Share | GB00B02LCQ05 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.15 | 4.62% | 3.40 | 3.30 | 3.40 | 3.35 | 3.25 | 3.25 | 1,483,036 | 16:35:02 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 59.59M | -43.07M | -0.0090 | -3.72 | 159.68M |
TIDMAGY
RNS Number : 3632P
Allergy Therapeutics PLC
05 June 2015
5 June 2015
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Company")
Acquisition of Alerpharma S.A.
Building towards a leading immunotherapy business in Spain
Allergy Therapeutics, the fully integrated specialty pharmaceutical company, today announces the acquisition of the entire issued share capital of Alerpharma, S.A. ("Alerpharma"), a privately owned company based in Spain for an initial consideration of EUR3.8 million (the "Acquisition"). Alerpharma wholly owns the Spanish-based allergy immunotherapy company Instituto de Immunologia y Alergia, S.A.U. ("Inmunal"), a spin-out from a world-leading biopharmaceutical company, Zeltia S.A. Group.
Inmunal is Alerpharma's principal operating subsidiary, and is highly regarded with well-established product lines in immunotherapy vaccines, bacteriological vaccines and diagnostics. Inmunal brings a newly-built state-of-the-art 2,200 sq m manufacturing facility in the Alcala de Henares Technological Park, Madrid, and a broad product range, including a specialised franchise on an olive vaccine, which is one of the most important allergens in southern Europe. The revenue producing product portfolio and the geographical presence of Inmunal complement Allergy Therapeutics' Spanish subsidiary, making the acquisition highly synergistic. The Acquisition also creates one of the leading immunotherapy companies in the Spanish market, estimated to be third largest in Europe with estimated annual sales of EUR72 million for 2014.
Alerpharma recorded unaudited turnover and pre-tax profits of approximately EUR4.5 million and EUR146,000 respectively in the financial year ended 31 December 2014, and its unaudited net assets as at 31 December 2014 were approximately EUR2.6 million. The Board expects the Acquisition to be immediately earnings enhancing.
The initial consideration for the Acquisition of EUR3.8 million was paid to the vendor (the "Vendor") in cash at completion, funded by the Company's operational cash flows. The total consideration includes a potential earn-out payment based on certain 2016 sales performance criteria, payable to the Vendor in 2017. The earn-out payment is estimated to be up to approximately EUR2 million, based on Alerpharma's forecast sales figures, funded by associated cash flows.
Manuel Llobet, Chief Executive Officer of Allergy Therapeutics, said:
"In addition to progressing with our US opportunity, building a strong business platform in Europe has been a top priority for our management team. Spain represents a very logical target market for Allergy Therapeutics because it is our second largest market after Germany, but it is where we currently have our lowest comparative market share. The Acquisition, therefore, provides us with the opportunity to grow our business in this important market. The combination of our Spanish subsidiary and Inmunal will provide us with significant cross selling opportunities and cost synergies, which will enhance our market share and increase our critical mass, enabling us to become one of the leading allergy immunotherapy companies in the Spanish market."
-Ends-
For further information
Allergy Therapeutics +44 (0) 1903 845 820 Manuel Llobet, Chief Executive Officer Ian Postlethwaite, Finance Director Panmure Gordon Freddy Crossley / Peter Steel / Duncan Monteith Corporate Finance +44 (0) 20 7886 2500 Tom Salvesen Corporate Broking FTI Consulting +44 (0) 20 3727 1000 Simon Conway / Mo Noonan / Victoria Foster Mitchell
Notes to editors
About Allergy Therapeutics
Allergy Therapeutics is a specialty pharmaceutical company focused on allergy vaccination. It has a growing business achieving revenue in the last financial year of GBP42 million mainly in Europe through its own sales and marketing infrastructure and further afield through distributors. It recently raised GBP20 million in April 2015 via a placing to continue with its clinical trials in the US.
About Alerpharma and Inmunal
Alerpharma, S.A., a privately owned company based in Spain, acquired Instituto de Immunologia y Alergia, S.A.U. (Inmunal), the Spanish-based allergy immunotherapy company in 2002. Inmunal was originally founded in 1989 by world-leading biopharmaceutical company, Zeltia S.A. Group. Alerpharma has 39 employees, with its headquarters in Parque Cientifico Tecnologico Alcala de Henares and a recently built a state-of-the-art 2,200 sq m manufacturing facility in the Alcala de Henares Technological Park, Madrid. In the financial year ended 31 December 2014, Alerpharma recorded sales of EUR4.5 million.
Inmunal, Alerpharma's principal operating subsidiary, focuses on immunotherapy vaccines, bacteriological vaccines and diagnostics, including a specialised franchise on an olive vaccine, one of the most important allergens in southern Europe. The Spanish immunotherapy market is estimated to be third largest in Europe with estimated annual sales of EUR72 million for 2014.
This information is provided by RNS
The company news service from the London Stock Exchange
END
ACQFAMLTMBAMMRA
1 Year Allergy Therapeutics Chart |
1 Month Allergy Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions